Abstract: A contoured composite structure includes an axis of curvature and at least one curved leg. The structure is fabricated by laying up a flat stack of prepreg fiber plies each having non-zero degree fiber orientations relative to an axis of curvature, and laying up at least one prepreg fiber ply on the stack having a zero degree fiber orientation. Laying up the zero degree ply includes placing prepreg tows in segments arranged end-to-end on at least a portion of the stack. The stack is formed into a web and a curved leg.

Abstract: A crisis management system may retrieve and analyze data from the social network system to identify, find, and/or locate individuals affected by a crisis. For example, when a crisis occurs, the crisis management system may retrieve data from a social network system regarding individuals that may be affected by the crisis. Crisis management system may then analyze the retrieved data to determine whether the individuals may have been located within the crisis area. Additionally, crisis management system may analyze the retrieved data to determine related individuals, such as co-workers, friends, family, relatives, or other individuals that may act as emergency contacts for the affected individuals.

Abstract: Bisacyloxycysteine type conjugates have been found to be useful as adjuvants and/or immunomodulators for prophylactic and/or therapeutic vaccination in the treatment of infectious diseases, inflammatory diseases, autoimmune diseases, tumors, and allergies, as well as in the control of fertility in human or animal populations. The compounds can be administered by system or mucosal routes and are particularly useful as mucosal adjuvants. These compounds can function as active ingredients in pharmaceutical compositions.

Abstract: A method for controlling sender events arriving at a recipient system is provided. An event transmitted from a sender is received at recipient system, and an event signature is determined. An elapse time between received event and a previous event is calculated. If elapse time is less than or equal to a critical time, it is determined if a counter is equal to or greater than a maximum value. If yes, event is rejected. If not, counter is incremented and the event is processed. If elapse time is greater than critical time, it is determined if elapse time is less than or equal to a grace period and if counter is greater than zero. If yes, counter is decremented and the event is processed. If not, counter is set to zero and event is processed. The critical time, maximum value, and increment/decrement factor are set based on the event signature.

Abstract: The present invention relates to new adjuvants and the uses in pharmaceutical compositions, like in vaccines. In particular, the present invention provides new compounds useful as adjuvants for prophylactic and/or therapeutic vaccination in the treatment of infectious diseases, inflammatory diseases, autoimmune diseases, tumours, allergies as well as for the control of fertility in human or animal populations. The compounds are particularly useful not only as systemic, but preferably as mucosal adjuvants. In addition, the invention relates to its uses as active ingredients in pharmaceutical compositions.

Abstract: A method and system for waste heat recovery for conversion to mechanical energy. Exhaust is received from an engine into a first heat exchanger where heat from the exhaust is transferred to a refrigerant. The exhaust is then transferred to a regenerator module in order to produce electricity which is provided to a power box. The hot refrigerant from the first heat exchanger is transferred to a kinetic energy recovery system to produce electricity which is also transferred to said power box. The power box provides electricity to a traction motor and the traction motor turns an axle. The refrigerant is then transferred to a refrigerant cooling unit and then to a second heat exchanger wherein ambient air from the regenerator module is cooled. The refrigerant and cooled ambient air can be then transferred to an engine cooling jacket to cool the engine.

Abstract: A method for controlling sender events arriving at a recipient system is provided. An event transmitted from a sender is received at recipient system, and an event signature is determined. An elapse time between received event and a previous event is calculated. If elapse time is less than or equal to a critical time, it is determined if a counter is equal to or greater than a maximum value. If yes, event is rejected. If not, counter is incremented and the event is processed. If elapse time is greater than critical time, it is determined if elapse time is less than or equal to a grace period and if counter is greater than zero. If yes, counter is decremented and the event is processed. If not, counter is set to zero and event is processed. The critical time, maximum value, and increment/decrement factor are set based on the event signature.

Abstract: In one embodiment, the present invention is a method and apparatus for multimedia collaboration using a social network system. In one embodiment, a method for using a social network to establish a collaborative multimedia interaction includes receiving a request from a user to establish the collaborative multimedia interaction, where the user has established the social network, and notifying one or more members of the social network of the collaborative multimedia interaction using, in some embodiments, information about the members' current or last known digital presence and a customizable set of notification rules.

Abstract: A method and apparatus for manufacturing a composite stringer. A composite material and foam are laid up onto a tool in the form of a stringer. The foam has a plurality of structural members within the foam. The plurality of structural members has a number of orientations to resist a number of loads. The composite material, the foam in the form of the stringer, and the plurality of structural members are cured to form the composite stringer.

Abstract: The present invention relates to adjuvants of the glycolipid type and their uses in pharmaceutical compositions, like in vaccines. In particular, the present invention provides new uses of compounds useful as adjuvants for prophylactic and/or therapeutic vaccination in the treatment of infectious diseases, inflammatory diseases, autoimmune diseases, tumours and allergies. The compounds are particularly useful not only as systemic, but preferably as mucosal adjuvants.

Abstract: The present invention relates to new adjuvants and the uses in pharmaceutical compositions, like in vaccines. In particular, the present invention provides new compounds useful as adjuvants and/or immunomodulators for prophylactic and/or therapeutic vaccination in the treatment of infectious diseases, inflammatory diseases, autoimmune diseases, tumours, allergies as well as for the control of fertility in human or animal populations. The compounds are particularly useful not only as systemic, but preferably as mucosal adjuvants. In addition, the invention relates to its uses as active ingredients in pharmaceutical compositions.

Abstract: The present invention relates to new adjuvants and the uses in pharmaceutical compositions, like in vaccines. In particular, the present invention provides new conjugates of the bisacyloxycysteine type useful as adjuvants and/or immunomodulators for prophylactic and/or therapeutic vaccination in the treatment of infectious diseases, inflammatory diseases, autoimmune diseases, tumours, allergies as well as for the control of fertility in human or animal populations. The compounds are particularly useful not only as systemic, but preferably as mucosal adjuvants. In addition, the invention relates to its uses as active ingredients in pharmaceutical compositions.

Abstract: The present invention relates to new adjuvants and the uses in pharmaceutical compositions, like in vaccines. In particular, the present invention provides new compounds useful as adjuvants and/or immunomodulators for prophylactic and/or therapeutic vaccination in the treatment of infectious diseases, inflammatory diseases, autoimmune diseases, tumors, allergies as well as for the control of fertility in human or animal populations. The compounds are particularly useful not only as systemic, but preferably as mucosal adjuvants. In addition, the invention relates to its uses as active ingredients in pharmaceutical compositions.

Abstract: The present invention relates to new adjuvants and the uses in pharmaceutical compositions, like in vaccines. In particular, the present invention provides new compounds useful as adjuvants for prophylactic and/or therapeutic vaccination in the treatment of infectious diseases, inflammatory diseases, autoimmune diseases, tumours, allergies as well as for the control of fertility in human or animal populations. The compounds are particularly useful not only as systemic, but preferably as mucosal adjuvants. In addition, the invention relates to its uses as active ingredients in pharmaceutical compositions.

Abstract: The present invention is directed to an attenuated Salmonella comprising a eukaryotic expression vector for delivery of the eukaryotic expression vector to a eukaryotic cell. Delivery may be to eukaryotic cells cultured in vitro or to cells in vivo, such as by oral administration of the attenuated Salmonella comprising the eukaryotic expression vector.

Abstract: Disclosed is the use of lipopeptides and lipoproteins as mucosal adjuvants for various vaccinations via mucous membranes, particularly intranasally. Said lipopeptides represent peptides or proteins substituted with 2,3-diacyloxy(2R)-propyl at the amino-terminal cystein of a peptide or protein, preferably S-(2,3-bispalmitoyloxy-(2R)-propyl)cysteinyl peptides derived from mycoplasmas. Said peptides are highly effective even in small doses, produce good immunization results, and increase the IgA level, among others.

Abstract: An attenuated strain of Salmonella typhimurium has been used as a vehicle for oral genetic immunization. Eukaryotic expression vectors containing the genes for b-galactosidase, or truncated forms of ActA and listeriolysin—two virulence factors of Listeria monocytogenes—that were controlled by an eukaryotic promoter have been used to transform a S. typhimurium aroA strain. Multiple or even single immunizations with these transformants induced a strong cytotoxic and helper T cell response as well as an excellent antibody response. Multiple immunizations with listeriolysin transformants protected the mice completely against a lethal challenge of L. monocytogenes. Partial protection was already observed with a single dose. ActA appeared not to be a protective antigen.

Abstract: A common problem in human vaccinology is the limited availability of efficient and non-toxic adjuvants capable of promoting mucosal responses. The potential usefulness of fibronectin-binding protein (SfbI) of Streptococcus pyogenes as immunological adjuvant was assessed using ovalbumin (OVA) as a model antigen. Mice were immunized by intranasal route either with soluble OVA or OVA covalently coupled to SfbI. Immunization with OVA-SfbI resulted in the elicitation of about 100-fold higher titres of anti-OVA serum IgG than using OVA alone. The anti-OVA IgG subclass pattern was dominated in both groups of mice by IgG1, followed by IgG2b, IgG2a, and IgG3. Immunization with OVA-SfbI also resulted in the elicitation of OVA-specific IgA in lung washes (24% of the total IgA), which was absent in mice immunized with OVA alone. Spleen cells from OVA-SfbI immunized mice also gave a much stronger proliferative response to in vitro restimulation with soluble OVA.

Abstract: Process and apparatus for the gaseous direct reduction of iron ores wherein at least a portion of the spent reducing gas effluent from a reduction reactor is upgraded and thereafter heated and recycled to said reactor forming a reducing gas loop and make-up reducing gas is added to said loop. The hot products of combustion, i.e., flue gases, in the reformer are used to heat the recycled gas (and optionally the quenched make-up gas) while maintaining independent control of the operating conditions of the reformer and gas heater to give improved thermal efficiency and fuel savings. The reformer has a stand-by stack through which the reformer flue gas is directed when the gas heater is shut down (to permit independent continuous operation of the reformer).

Abstract: Process and apparatus for the gaseous direct reduction of iron ores wherein at least a portion of the spent reducing gas effluent from a reduction reactor is upgraded and thereafter heated and recycled to said reactor forming a reducing gas loop and make-up reducing gas is added to said loop. The hot products of combustion, i.e., flue gases, in the reformer are used to heat the recycled gas (and optionally the quenched make-up gas) while maintaining independent control of the operating conditions of the reformer and gas heater to give improved thermal efficiency and fuel savings. The reformer has a stand-by stack through which the reformer flue gas is directed when the gas heater is shut down (to permit independent continuous operation of the reformer).